Abstract
Early, simple predictors for long-term survival in Parkinson's disease (PD) may help identify patients at elevated risk and are crucial for more personalized treatment. This large, retrospective study examined whether higher levodopa equivalent daily dose (LEDD) a year after diagnosis predicts long-term survival. Mortality risk was increased among 292 patients receiving≥600mg LEDD versus 2233 patients receiving<600mg LEDD (hazard ratio 1.5; 95% confidence interval 1.3-1.7), particularly among patients aged<75years (1.8; 1.4-2.4). In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
